

The MIT-E Study needs you!

Helping you find strength to
break the cycle of mitochondrial
disease-associated epilepsy



For more information about this study, please contact:

medinfo@ptcbio.com

+1-866-562-4620

Additional study information and participating sites:

www.themit-estudy.com

Participants will be reimbursed for costs associated with taking part in the study.

Sponsor

PTC Therapeutics, Inc.



PTC Therapeutics would like to express their gratitude to all those who have considered participation in the MIT-E Study. PTC remains committed to the Mitochondrial Disease Community.

Introducing the MIT-E Study

is pleased to share information about a clinical trial opportunity for patients with mitochondrial disease with hard-to-treat epilepsy.

The goal of the **MIT-E Study** is to find out whether an investigational drug, vatiquinone (PTC743), is safe and helps to reduce seizures in patients who have mitochondrial disease with hard-to-treat epilepsy.

Study summary:

The study includes:

- **5–6-weeks** "Screening" phase before the main study, to find out the participant's usual seizure frequency and give training to parents/caregivers on how to record seizures.
- **24-weeks** phase during which participants will receive **either vatiquinone or placebo** (there is a 50% chance of participants receiving the placebo. This looks exactly like vatiquinone but contains no active ingredient).
- An option to enter **48-weeks** extension to the study in which **all participants will receive vatiquinone**.

To learn more about this study, contact:

medinfo@ptcbio.com

+1-866-562-4620

Around 60 children and teenagers will take part at approximately 12 study centers across the globe.

To be able to take part, participants must:

- Be under 18 years of age
- Have inherited mitochondrial disease with associated epilepsy
- Have had epilepsy associated with mitochondrial disease for at least 6 months

Please see **www.themit-estudy.com** for a detailed list of specific inclusion and exclusion criteria.

